Abstract 5856: Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class EGFR/cMet bispecific antibody-drug conjugate

Abstract Introduction: High toxin potency in antibody-drug conjugates (ADCs) limits clinical doses to those below optimal antibody levels, diminishing signal blockade potential and emphasizing chemotherapeutic effects. To address this limitation, we developed Hanjugator, a customizable, modular camptothecin-based linker-payload platform with tunable potency—from threefold lower than deruxtecan to comparable with exatecan—enabling a broader therapeutic window and preserving antibody functionality. We applied medium-potency payload to an EGFR/cMet bispecific ADC, a target combination known to require higher clinical doses for optimal receptor occupancy and efficacy. Methods: Cytotoxicity of toxin candidates and ADCs was assessed via CellTiter-Glo (CTG) assay in immortalized cell lines. ADC binding and internalization were evaluated by flow cytometry on cells with varying antigen expression levels. Pharmacokinetics (PK) of LPA003-based ADC were determined in rats following single intravenous 5 mg/kg dosing. Bystander killing was quantified by co-incubating antigen-positive and -negative (Jurkat) cells, with Jurkat viability measured via CTG assay. In vivo efficacy of EGFR/cMet-LPA003 was tested in multiple xenograft models (LU387, SW48, HT29, NCI-H1975). For preliminary toxicology, cynomolgus monkeys were treated with three doses of 30 or 60 mg/kg of the test article, administered every three weeks (Q3W). Results: The Hanjugator platform delivers a series of highly hydrophilic linker-payloads with excellent compatibility for non-standard, hydrophobic antibodies and superior thermal, plasma, and freeze-thaw stability. These conjugates exhibit bystander killing over 10-fold stronger compared with deruxtecan and outperform multiple clinical-stage linker-payload systems in efficacy studies, despite some competitors’ higher intrinsic payload potency. The platform’s wide toxin potency range broadens its applications. Medium-potency LPA003, conjugated to EGFR/cMet bispecific antibody, induced significant tumor regression at single 3 mg/kg doses in various xenograft models, outperforming AZD9592 in the HT29 CDX model. Preliminary toxicology shows EGFR/cMet-LPA003 is well tolerated in cynomolgus monkeys after 3 doses at 60 mg/kg Q3W. Conclusion: We have developed Hanjugator, a versatile camptothecin-based linker-payload platform with tunable toxin potency. This modular design accommodates diverse targets and ADC programs, optimizing dosing regimens and broadening clinical applications. The LPA003-conjugated EGFR/cMet bispecific ADC exhibits a superior therapeutic index, maximizing antibody-mediated signaling blockade, and positions as best-in-class molecule with Investigational New Drug submission anticipated in Q1 2026. Citation Format: Rui Liu, Ge Song, Yushi Chi, Lingli Zhang, Fan Yang, Junjie Zhang, Boqi Gu, Chencheng Han, Xiayan Zhang, Wan-jen Yang, Xiaomu Cheng, Xiaoling Yuan, Yi Zhang, Zhiliang Lv, Qian Zou, Huixin Yan, Chen Hu, Jijun Yuan, . Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class EGFR/cMet bispecific antibody-drug conjugate [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5856.